ITRM: 25-NSE · delisting
Nasdaq has determined to remove the ordinary shares of Iterum Therapeutics plc from listing effective at the opening of the trading session on July 6, 2026. The exchange determined the company no longer qualified for listing pursuant to Listing Rule 5550(a)(2). Iterum Therapeutics was initially notified of this determination on February 24, 2026, and appealed to the Listing Qualifications Hearings Panel, but subsequently withdrew its appeal on March 27, 2026. As a result of the withdrawn appeal, Nasdaq informed the company that its shares would be suspended, with trading ceasing on April 1, 2026.
Iterum files wind-up petition due to limited cash, inability to raise equity
Iterum Therapeutics Announces Filing of Winding Up Petition
Iterum Therapeutics Provides Business Update
